Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa

BMC Psychiatry

Ayesha A Motala¹  Jonathan K Burns²  Shamima Saloojee² 

[1] Department of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu - Natal, Durban, South Africa;Department of Psychiatry, Nelson R Mandela School of Medicine, University of KwaZulu – Natal, Private bag X3, Congella, Durban, 4013, South Africa

关键词: Antipsychotics;    Severe mental illness;    Screening;    Metabolic syndrome;   

Others  :  1123397
DOI  :  10.1186/s12888-014-0228-5

 received in 2014-02-07, accepted in 2014-08-04,  发布年份 2014

【 摘 要 】

Background

Sub Saharan African is experiencing the largest increase in the prevalence of type 2 diabetes mellitus and cardiovascular disease globally. Metabolic syndrome (MetS) is a cluster of risk factors for these conditions. There is a consistently higher prevalence of cardiometabolic disease among individuals with severe mental illness (SMI) compared to the general population worldwide .However, it is known from research in high income countries that screening for MetS in patients with SMI is low. The objective of this study was to document the extent of the expected low frequency of testing for all the components of the metabolic syndrome (MetS) in patients with SMI in a low middle income country.

Methods

This was a cross sectional study, undertaken from January to June 2012 on out-patients with SMI who were treated with antipsychotic medication for at least 6 months. The study measured the proportion of participants who were tested for MetS in the previous year.

Results

The study included 331 (M: F; 167:164) participants with a mean age of 35.2 ± 11.98 years. The majority (78.8%) were black South Africans. Only 2 subjects (0.6%) were screened for all five components of MetS. Regarding the individual components, 99%, 0.6%, 3.9% and 1.8% were screened for raised blood pressure, abdominal obesity, hyperglycaemia, hypertriglyceridaemia and decreased high density lipoprotein cholesterol respectively.

Conclusion

It is unacceptable that less than one percent of our participants were adequately screened for modifiable risk factors for type 2 diabetes mellitus and cardiovascular disease which are the most common causes of mortality among patients with SMI. These results highlight the need for translating guidelines into action in low and middle income countries.

【 授权许可】

   
2014 Saloojee et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Weiping Y, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophr Bull 2013, 39(2):306-318.
• [2]Maaroganye K, Mohapi M, Kruger C, Rheeder P: The prevalence of metabolic syndrome and its associated factors in long -term patients in a specialist psychiatric hospital in South Africa. Afr J Psychiatry 2013, 16:414-423.
• [3]Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M: Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol 2006, 41:457-463.
• [4]Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [5]DeHert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S: Physical illness in patients with severe mental disorders I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10:52-77.
• [6]Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009, 119:171-179.
• [7]Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia : a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233.
• [8]De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, Van Winkel R, Mitchell AJ: Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011, 199:99-105.
• [9]Clark M, Dubowski K, Colmore J: The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970, 11:883-889.
• [10]Mitchell AJ, Dellafon D, Vancamfort D, Correll CU, DeHert M: Guideline concomitant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of monitoring practices. Psychol Med 2012, 42(01):125-147.
• [11]De Hert MA, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Möller H-J, Gautam S, Detraux J, Correll CU: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011, 10(2):138-151.
• [12]Suppes T, McElroy S, Hirschfeld R: Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder, a survey of 500 US psychiatrists. Psychopharmacol Bull 2007, 40:22-37.
• [13]Davis S: Diabetogenic drugs: treating chronic conditions to minimize new onset diabetes. S Afr Pharm J 2012, 79(3):24-26.
• [14]Ludwick JJ, Oosthuizen PP: Screening for and monitoring of cardio -metabolic risk factors in outpatients with severe mental illness in a primary care setting. Afr J Psychiatry 2009, 12:287-292.
• [15]Marsay C, Szabo CP: Screening for metabolic syndrome-adherence to guidelines. Afr J Psychiatry 2011, 14:64-66.
• [16]Singh D, Berkman A, Bresnahan M: Seroprevalence and HIV –associated factors among adults with severe mental illness- a vulnerable population. S Afr Med J 2009, 99:523-527.
• [17]Khatana S, Kane J, Taveira T, Bauer M, Wu W: Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One 2011, 6:e19298.
• [18]Shi L, Ascher-Svanum H, Chiang Y, Zhao Y, Fonseca V, Winstead D: Predictors of metabolic monitoring among schizophrenia patients with a new episode of second - generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 2009, 9:80.
• [19]Mittal D, Chenghui L, Williams JS, Viverito K, Landes RD, Owen RR: Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psych Services 2013, 64(1):28-35.
• [20]Bobes J, Alegrı’a A, Saiz-Gonzalez M, Barber I, Pe’rez J, Saiz-Ruiz J: Change in psychiatrists attitudes towards the physical health of patients with Schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Euro Psychiat 2010, 26(5):305-312.
• [21]Gonzalez C, Ahammed N, Fisher R: Improving physical health monitoring for out patients on antipsychotic medication. Psychiatr Bull 2010, 34:91-94.
• [22]Morrato EH, Druss B, Hartung D, Valuck RJ, Allen R, Campagna E, Newcomer J: Metabolic testing rates in 3 state Medicaid programmes after FDA warnings and ADA/APA recommendations for second –generation antipsychotic drugs. Arch Gen Psychiatry 2010, 67(1):17-24.
• [23]Haupt D, Rosenblatt L, Kim E, Baker R, Whitehead R, Newcomer J: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second generation antipsychotic agents. Am J Psychiat 2009, 166:345-353.
• [24]Mackin P, Bishop D, Watkinson H: A prospective study of monitoring practices for metabolic disease in antipsychotic - treated community psychiatric patients. BMC Psychiatry 2007, 25:7-28.
• [25]Nguyen D, Brakoulias V, Boyce P: An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry 2009, 17:295-299.
• [26]Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA: Dyslipidaemia independent of body mass in antipsychotic treated patients under real-life conditions. J Clin Psychopharmacol 2008, 28:132-137.
• [27]Gul M, Nihgam A, Broughton N: Clinical monitoring of patients on clozapine. J Pakistan Psychiatr Soc 2006, 3:90.
• [28]Young Kim J, Hi Kim S, Jeong Cho : Socioeconomic Status in Association with Metabolic Syndrome and Coronary Heart Disease Risk. Korean J Fam Med 2013, 34(2):131-138.
• [29]Joshi A, Mehta S, Grover A, Talati K, PuricelliPerin DM, Malhotra B: Knowledge, attitude, and practices of individuals to prevent and manage metabolic syndrome in an Indian setting. Diabetes Technol Ther 2013, 15(8):644-653.
• [30]Druss BG, Zhao I, Cummings JR, Shim RS, Rust GS, Marcus SC: Mental Comorbidity and Quality of Diabetes Care Under Medicaid: A 50-State Analysis. Med Care 2012, 50(5):428-433.
• [31]Schneiderhan ME, Batscha CL, Rosen C: Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy 2009, 29(8):975-987.
• [32]Davis K: Emphasizing holistic care: A mental healthcare provider integrates physical healthcare into its services. Behav Healthc 2009, 29(3):38-39.
• [33]Keenan TE, Yu A, Cooper LA, Appel LJ, Guallar E, Gennusa JV III, Dickerson FB, Crum RM, Anderson CA, Campbell LM, Young DR, Daumit GL: Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population. Schizophr Res 2013, 15(1):211-216.
• [34]Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al.: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.
• [35]Motala AA, Pirie FJ, Esterhuizen T, Omar MAK: The prevalence of metabolic syndrome and determination of the optimal waist circumference cut off points in a rural South African community. Diabetes Care 2011, 34(4):1032-1037.